ID   NK-YS
AC   CVCL_8461
AS   CVCL_AX40
SY   NKYS
DR   cancercelllines; CVCL_8461
DR   Cosmic; 1534872
DR   Cosmic; 1542075
DR   Cosmic; 2025325
DR   Cosmic; 2390119
DR   Cosmic; 2785205
DR   GEO; GSM472002
DR   GEO; GSM3021082
DR   Progenetix; CVCL_8461
DR   Wikidata; Q54930662
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RX   PubMed=9694726;
RX   PubMed=10803505;
RX   PubMed=19194464;
RX   PubMed=21052088;
RX   PubMed=25586472;
CC   Population: Japanese.
CC   Characteristics: IL2 dependent.
CC   Doubling time: ~48 hours (PubMed=9694726).
CC   Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).
CC   Omics: Transcriptomics; Microarray.
CC   Omics: Variations; CNV analysis.
CC   Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.
CC   Cell type: NK T-cell; CL=CL_0000814.
DI   NCIt; C4684; Nasal type extranodal NK/T-cell lymphoma
DI   ORDO; Orphanet_86879; Extranodal nasal NK/T cell lymphoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   19Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 10-04-25; Version: 17
//
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RA   Drexler H.G.;
RT   "The leukemia-lymphoma cell line factsbook.";
RL   (In book) ISBN 9780122219702; pp.1-733; Academic Press; London; United Kingdom (2001).
//
RX   PubMed=9694726; DOI=10.1182/blood.V92.4.1374;
RA   Tsuchiyama J., Yoshino T., Mori M., Kondoh E., Oka T., Akagi T.,
RA   Hiraki A., Nakayama H., Shibuya A., Ma Y.-X., Kawabata T., Okada S.,
RA   Harada M.;
RT   "Characterization of a novel human natural killer-cell line (NK-YS)
RT   established from natural killer cell lymphoma/leukemia associated with
RT   Epstein-Barr virus infection.";
RL   Blood 92:1374-1383(1998).
//
RX   PubMed=10803505; DOI=10.1038/sj.leu.2401778;
RA   Drexler H.G., Matsuo Y.;
RT   "Malignant hematopoietic cell lines: in vitro models for the study of
RT   natural killer cell leukemia-lymphoma.";
RL   Leukemia 14:777-782(2000).
//
RX   PubMed=19194464; DOI=10.1038/leu.2009.3;
RA   Iqbal J., Kucuk C., Deleeuw R.J., Srivastava G., Tam W., Geng H.-M.,
RA   Klinkebiel D.L., Christman J.K., Patel K.N., Cao K., Shen L., Dybkaer K.,
RA   Tsui I.F.L., Ali H.H., Shimizu N., Au W.Y., Lam W.L., Chan W.-C.;
RT   "Genomic analyses reveal global functional alterations that promote
RT   tumor growth and novel tumor suppressor genes in natural killer-cell
RT   malignancies.";
RL   Leukemia 23:1139-1151(2009).
//
RX   PubMed=21052088; DOI=10.1038/leu.2010.255;
RA   Iqbal J., Weisenburger D.D., Chowdhury A., Tsai M.-Y., Srivastava G.,
RA   Greiner T.C., Kucuk C., Deffenbacher K.E., Vose J.M., Smith L., Au W.Y.,
RA   Nakamura S., Seto M., Delabie J., Berger F., Loong F., Ko Y.-H.,
RA   Sng I., Liu X., Loughran T.P. Jr., Armitage J.O., Chan W.-C.;
RT   "Natural killer cell lymphoma shares strikingly similar molecular
RT   features with a group of non-hepatosplenic gammadelta T-cell lymphoma
RT   and is highly sensitive to a novel aurora kinase A inhibitor in
RT   vitro.";
RG   International Peripheral T-cell Lymphoma Project;
RL   Leukemia 25:348-358(2011).
//
RX   PubMed=25586472; DOI=10.1038/ncomms7025; PMCID=PMC7743911;
RA   Kucuk C., Jiang B., Hu X.-Z., Zhang W.-Y., Chan J.K.C., Xiao W.-M.,
RA   Lack N., Alkan C., Williams J.C., Avery K.N., Kavak P., Scuto A.,
RA   Sen E., Gaulard P., Staudt L.M., Iqbal J., Zhang W.-W., Cornish A.,
RA   Gong Q., Yang Q.-P., Sun H., d'Amore F.A., Leppa S., Liu W.-P., Fu K.,
RA   de Leval L., McKeithan T.W., Chan W.-C.;
RT   "Activating mutations of STAT5B and STAT3 in lymphomas derived from
RT   gammadelta-T or NK cells.";
RL   Nat. Commun. 6:6025.1-6025.12(2015).
//